Mumbai, June 14, 2013 - Merial, the animal health division of Sanofi, today
announced the approval and closing of Merial’s acquisition of the animal health
division of Dosch Pharmaceuticals Private Limited, creating for Merial a market
entry in India’s growing animal health market.
The signing of a binding
agreement leading up to the acquisition was announced in December 2012. Merial
and Dosch have now completed all regulatory approvals required for the closing
of the acquisition.
The acquired business, now the
animal health division of Sanofi Synthelabo India, will commence marketing
Dosch’s 86 animal health products and 50 brands for ruminants, poultry and
companion animals, as well as continue the process of registering Merial brands
for companion and production animals for commercialization in India.
Dosch animal health division
CEO, Dr. Sharat Tugnait, and his management team will continue to oversee the
combined Merial/Dosch operations in Mumbai, India, under the executive
direction of Merial India country manager, Mayank Parekh.
Merial, a Sanofi company is a
world-leading, innovation-driven animal health company, providing a
comprehensive range of products to enhance the health, well-being and
performance of a wide range of animals. Merial employs approximately 5,600
people and operates in more than 150 countries worldwide. Its 2012 sales were €2.2
billion ($2.8 billion). For more information, please see www.merial.com.
global and diversified healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients’ needs. Sanofi has core strengths in
the field of healthcare with seven growth platforms: diabetes solutions, human
vaccines, innovative drugs, consumer healthcare, emerging markets, animal
health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in
New York (NYSE: SNY).
Contact: SANOFI INDIA
|Senior Director-Communications & Public Affairs